Testicular Volume Assessment and Management

Introduction to Testicular Volume Guidelines

The European Germ Cell Cancer Consensus Group recommends using a cut-off value of 12 mL to define testicular atrophy and stratify cancer risk 1, 2

Men with testicular volume <12 mL and age <30 years have a >34% risk of harboring testicular intraepithelial neoplasia (TIN) in the contralateral testis when presenting with a testicular tumor 1, 2
The European Germ Cell Cancer Consensus Group uses the 12 mL threshold to identify high-risk patients requiring testicular biopsy 1, 2

For men age <30 years with volume 10-12 mL, strongly consider testicular biopsy if the patient has additional risk factors: history of cryptorchidism, infertility, contralateral testicular tumor, or extragonadal germ cell tumor 1, 2
For men age ≥30 years with volume 10-12 mL, testicular biopsy is recommended for infertile men with testicular volume <12 mL who belong to higher-risk groups 4

Perform comprehensive fertility evaluation if conception is desired, including semen analysis, FSH, LH, and testosterone levels 3
Scrotal ultrasound is indicated to assess testicular architecture, detect microlithiasis, and evaluate for masses when physical examination is difficult 3
Genetic testing (karyotype and Y-chromosome microdeletion) is mandatory if azoospermia or severe oligospermia is present 3

Do not dismiss volumes of 10-12 mL as "normal variation" in young men (<30 years) with additional risk factors—the TIN risk exceeds 34% 1, 2
Do not perform routine testicular biopsy in men >30 years without other risk factors, as this represents unnecessary intervention 1, 2
Do not use FSH levels alone to determine whether spermatogenesis is present, as men with maturation arrest can have normal FSH despite severe dysfunction 3
Do not initiate testosterone replacement therapy in men with reduced testicular volume who desire fertility, as this will further suppress spermatogenesis 3